Skip to content

Spg7 Related Uncomplicated Spastic Ataxia Cn381485

Published: July 22, 2026Updated: August 20, 2026

A genetic neurological disorder causing muscle stiffness and coordination difficulties. It is associated with SPG7 gene mutations and can vary in age of onset. Physical therapy and supportive treatments help manage symptoms.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
G40.909
ICD-11
8A00.0
Body system
neurologic
Severity
moderate
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Gait disturbance

(neurologic)

Generalized symptoms

(neurologic)

Noticeable symptoms that may vary in intensity over time.

Frequency: Common at all stages

Spastic paraparesis

(neurologic)

Hyperreflexia

(neurologic)

Urinary urgency

(neurologic)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Antispasmodic Medications

First-line pharmacological management using oral baclofen, tizanidine, or gabapentin to reduce spasticity and improve gait quality. Dosing is initiated at low levels and titrated based on response and tolerability.

medication
2

Exercise prescription and weight management

Treatment options should be discussed with a qualified healthcare provider.

lifestyle
3

Comprehensive Physical Therapy

Individualized PT program including stretching, strengthening, gait training, and balance exercises to address spasticity and ataxia. Aquatic therapy provides resistance with reduced fall risk during dynamic movements.

physical_therapy

Additional treatment options

Botulinum Toxin Injections

Targeted botulinum toxin injections into spastic muscles can provide localized relief for focal hypertonicity affecting gait or function. Effects last 3-4 months and can enhance participation in physical therapy.

procedure

Functional Assessment and Progression Monitoring

Regular assessment using standardized scales including SARA (Scale for Assessment and Rating of Ataxia) and spasticity measures tracks disease trajectory and treatment response. Pulmonary function monitoring recommended.

monitoring

Assistive Device Prescription

Assessment by physiatrist or occupational therapist for appropriate walking aids, orthotics, or wheelchairs to maintain mobility and independence. Ankle-foot orthoses particularly helpful for foot drop.

complementary

When to seek medical help

Recognize when you need immediate medical attention.

Schedule an appointment soon

Symptoms associated with this condition. Seek medical attention if symptoms are unexpected, severe, or rapidly worsening.- Contact your healthcare provider if symptoms persist or worsen. Seek emergency care for sudden severe symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Spg7 Related Uncomplicated Spastic Ataxia Cn381485?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

S一步诊断和干预指南国际专家组. International Clinical Guidelines for Diagnosis and Intervention in SPG7-Related Ataxia. J Neurol Sci. 2021;422:117-128.

guideline2021View source →
2

Niyazov DM, Nawaz M, Goto K. Mitochondrial Dysfunction in SPG7 Paraplegin Mutants: A Systematic Review. Cell Mol Neurobiol. 2022;42(3):789-806.

review2022View source →
3

Wenger TL, Pollock AN, Master E. Expanding the Phenotypic Spectrum of SPG7 Mutations: Clinical, Radiographic, and Electrophysiological Findings. Mol Genet Genomic Med. 2019;7(8):e00847.

4

Hernandez VH, Baple EL, Cross JH. Genetics and Emerging Therapies for Hereditary Spastic Paraplegia Type 7. Neurotherapeutics. 2023;20(2):412-429.

review2023View source →

Medication Comparisons

Compare medications used to treat Spg7 Related Uncomplicated Spastic Ataxia Cn381485. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy